黄芪多糖对糖尿病肾病信号通路的干预作用研究进展
Research Progress on the Intervention of Astragalus Polysaccharides in Diabetic Nephropathy-Related Signaling Pathways
DOI: 10.12677/acm.2025.1572153, PDF,   
作者: 纪心昊：黑龙江中医药大学研究生院，黑龙江 哈尔滨；马国庆*：黑龙江中医药大学附属第二医院内分泌科，黑龙江 哈尔滨
关键词: 糖尿病肾病；黄芪多糖；信号通路；肾脏保护；Diabetic Nephropathy； Astragalus Polysaccharide； Signaling Pathways； Renal Protection
摘要: 糖尿病肾病(DN)是糖尿病常见的并发症之一，也是导致末期肾病的主要因素。黄芪多糖(APS)作为一种具有多种生物活性的中草药成分，已被证实对DN具有潜在的治疗效果。本研究综述了APS在DN治疗中的信号调控机制，包括TGF-β/Smads、TLR4/NF-κB、Sirt1/FoxO1、Gm41268/PRLR和Wnt信号通路，这些通路与肾脏炎症、纤维化、细胞凋亡等病理生理过程密切相关。APS通过多途径、多靶点调控上述信号通路，展现出一定的肾脏保护作用，其可能对延缓糖尿病肾病进展具有积极意义。尽管APS在DN治疗中的应用潜力巨大，但仍需进一步深入研究其调控机制、药理学特性、药代动力学特点、临床有效性和安全性。本综述为APS在DN治疗中的潜在应用提供了理论依据，并指出了未来研究的方向。
Abstract: Diabetic nephropathy (DN) is a common complication of diabetes and a leading cause of end-stage kidney disease. Astragalus polysaccharide (APS), as a traditional Chinese medicinal herb with various bioactivities, has been demonstrated to possess potential therapeutic effects on DN. This review summarizes the signaling regulation mechanisms of APS in the treatment of DN, including the TGF-β/Smads, TLR4/NF-κB, Sirt1/FoxO1, Gm41268/PRLR, and Wnt signaling pathways, which are closely related to pathological processes such as renal inflammation, fibrosis, and apoptosis. APS regulates the above signaling pathways through multiple pathways and targets, showing certain renal protective effects, and may positively help delay the progression of diabetic nephropathy. Although the application potential of APS in the treatment of DN is enormous, further in-depth studies are needed to elucidate its regulatory mechanisms, pharmacological properties, pharmacokinetic characteristics, clinical efficacy, and safety. This review provides a theoretical basis for the potential application of APS in the treatment of DN and points out the direction for future research.
文章引用：纪心昊, 马国庆. 黄芪多糖对糖尿病肾病信号通路的干预作用研究进展[J]. 临床医学进展, 2025, 15(7): 1496-1502. https://doi.org/10.12677/acm.2025.1572153

参考文献

[1] DeFronzo, R.A., Reeves, W.B. and Awad, A.S. (2021) Pathophysiology of Diabetic Kidney Disease: Impact of SGLT2 Inhibitors. Nature Reviews Nephrology, 17, 319-334. [Google Scholar] [CrossRef] [PubMed]
[2] Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B.B., et al. (2023) Erratum to “IDF Diabetes Atlas: Global, Regional and Country-Level Diabetes Prevalence Estimates for 2021 and Projections for 2045” [Diabetes Res. Clin. Pract. 183 (2022) 109119]. Diabetes Research and Clinical Practice, 204, Article ID: 110945. [Google Scholar] [CrossRef] [PubMed]
[3] Gupta, S., Dominguez, M. and Golestaneh, L. (2023) Diabetic Kidney Disease: An Update. Medical Clinics of North America, 107, 689-705. [Google Scholar] [CrossRef] [PubMed]
[4] Hung, P., Hsu, Y., Chen, T. and Lin, C. (2021) Recent Advances in Diabetic Kidney Diseases: From Kidney Injury to Kidney Fibrosis. International Journal of Molecular Sciences, 22, Article No. 11857. [Google Scholar] [CrossRef] [PubMed]
[5] Ricciardi, C.A. and Gnudi, L. (2021) Kidney Disease in Diabetes: From Mechanisms to Clinical Presentation and Treatment Strategies. Metabolism, 124, Article ID: 154890. [Google Scholar] [CrossRef] [PubMed]
[6] Tang, G., Li, S., Zhang, C., Chen, H., Wang, N. and Feng, Y. (2021) Clinical Efficacies, Underlying Mechanisms and Molecular Targets of Chinese Medicines for Diabetic Nephropathy Treatment and Management. Acta Pharmaceutica Sinica B, 11, 2749-2767. [Google Scholar] [CrossRef] [PubMed]
[7] 姚琼, 叶太生, 张莹雯, 等. 基于网络药理学及Akt1/mTOR自噬通路探讨黄芪减少糖尿病肾病蛋白尿的作用机制[J]. 世界科学技术-中医药现代化, 2021, 23(8): 2699-2710.
[8] Tian, H., Lu, J., He, H., Zhang, L., Dong, Y., Yao, H., et al. (2016) The Effect of Astragalus as an Adjuvant Treatment in Type 2 Diabetes Mellitus: A (Preliminary) Meta-Analysis. Journal of Ethnopharmacology, 191, 206-215. [Google Scholar] [CrossRef] [PubMed]
[9] Du, Y., Wan, H., Huang, P., Yang, J. and He, Y. (2022) A Critical Review of Astragalus Polysaccharides: From Therapeutic Mechanisms to Pharmaceutics. Biomedicine & Pharmacotherapy, 147, Article ID: 112654. [Google Scholar] [CrossRef] [PubMed]
[10] 纪新建, 张志芳, 闫鑫媛, 等. 基于肠道微生态探讨黄芪扶正调衡治疗糖尿病肾病的研究进展[J]. 中国微生态学杂志, 2024, 36(8): 967-973.
[11] 李杰辉, 梁彬, 陈壮丽, 等. MEBO对大鼠糖尿病性创面组织中miRNA-21及其靶标TGF-β1/Smads信号通路的影响[J]. 中国老年学杂志, 2024, 44(18): 4448-4452.
[12] Voelker, J., Berg, P.H., Sheetz, M., Duffin, K., Shen, T., Moser, B., et al. (2016) Anti-TGF-β1 Antibody Therapy in Patients with Diabetic Nephropathy. Journal of the American Society of Nephrology, 28, 953-962. [Google Scholar] [CrossRef] [PubMed]
[13] 郭帅, 方敬, 陈志强. TGF-β1介导的Smad和ERK信号通路在肾纤维化中的研究进展[J]. 中国免疫学杂志, 2022, 38(6): 766-770.
[14] 李承德, 王煜, 曲敬蓉, 等. 黄芪多糖对糖尿病大鼠肾脏TGF-β1/Smads信号通路的影响[J]. 中国药理学通报, 2018, 34(4): 512-516.
[15] Nie, Y., Li, S., Yi, Y., Su, W., Chai, X., Jia, D., et al. (2014) Effects of Astragalus Injection on the TGFβ/Smad Pathway in the Kidney in Type 2 Diabetic Mice. BMC Complementary and Alternative Medicine, 14, Article No. 148. [Google Scholar] [CrossRef] [PubMed]
[16] Zhang, Y., Alexander, P.B. and Wang, X. (2016) TGF-β Family Signaling in the Control of Cell Proliferation and Survival. Cold Spring Harbor Perspectives in Biology, 9, a022145. [Google Scholar] [CrossRef] [PubMed]
[17] 张洪江, 凃影叶, 杜飞, 等. TGF-β参与糖尿病肾病的发生发展的机制研究现状[J]. 生命科学, 2020, 32(2): 179-187.
[18] Lin, M., Yiu, W.H., Wu, H.J., Chan, L.Y.Y., Leung, J.C.K., Au, W.S., et al. (2012) Toll-Like Receptor 4 Promotes Tubular Inflammation in Diabetic Nephropathy. Journal of the American Society of Nephrology, 23, 86-102. [Google Scholar] [CrossRef] [PubMed]
[19] Faure, E., Equils, O., Sieling, P.A., Thomas, L., Zhang, F.X., Kirschning, C.J., et al. (2000) Bacterial Lipopolysaccharide Activates NF-κB through Toll-Like Receptor 4 (TLR-4) in Cultured Human Dermal Endothelial Cells. Differential Expression of TLR-4 and TLR-2 in Endothelial Cells. Journal of Biological Chemistry, 275, 11058-11063. [Google Scholar] [CrossRef] [PubMed]
[20] Shimamoto, A., Chong, A.J., Yada, M., Shomura, S., Takayama, H., Fleisig, A.J., et al. (2006) Inhibition of Toll-Like Receptor 4 with Eritoran Attenuates Myocardial Ischemia-Reperfusion Injury. Circulation, 114, I-270-I-274. [Google Scholar] [CrossRef] [PubMed]
[21] 高海洋, 陈曦, 张金存, 等. 隐丹参酮调节HMGB1/TLR4/NF-κB信号通路对单侧输尿管梗阻大鼠肾间质纤维化的影响[J]. 中国老年学杂志, 2024, 44(18): 4516-4520.
[22] Guo, M., Gao, J., Jiang, L. and Dai, Y. (2023) Astragalus Polysaccharide Ameliorates Renal Inflammatory Responses in a Diabetic Nephropathy by Suppressing the TLR4/NF-κB Pathway. Drug Design, Development and Therapy, 17, 2107-2118. [Google Scholar] [CrossRef] [PubMed]
[23] Du, L., Qian, X., Li, Y., Li, X., He, L., Xu, L., et al. (2020) Sirt1 Inhibits Renal Tubular Cell Epithelial-Mesenchymal Transition through YY1 Deacetylation in Diabetic Nephropathy. Acta Pharmacologica Sinica, 42, 242-251. [Google Scholar] [CrossRef] [PubMed]
[24] Li, X., Li, Y., Hao, Q., Jin, J. and Wang, Y. (2024) Metabolic Mechanisms Orchestrated by Sirtuin Family to Modulate Inflammatory Responses. Frontiers in Immunology, 15, Article ID: 1448535. [Google Scholar] [CrossRef] [PubMed]
[25] Huang, K., Huang, J., Xie, X., Wang, S., Chen, C., Shen, X., et al. (2013) Sirt1 Resists Advanced Glycation End Products-Induced Expressions of Fibronectin and TGF-β1 by Activating the Nrf2/ARE Pathway in Glomerular Mesangial Cells. Free Radical Biology and Medicine, 65, 528-540. [Google Scholar] [CrossRef] [PubMed]
[26] Zhang, L., Chen, Z., Gong, W., Zou, Y., Xu, F., Chen, L., et al. (2018) Paeonol Ameliorates Diabetic Renal Fibrosis through Promoting the Activation of the Nrf2/ARE Pathway via Up-Regulating Sirt1. Frontiers in Pharmacology, 9, Article No. 512. [Google Scholar] [CrossRef] [PubMed]
[27] Liu, H., Kao, H. and Wu, C. (2019) Exercise Training Upregulates SIRT1 to Attenuate Inflammation and Metabolic Dysfunction in Kidney and Liver of Diabetic db/db Mice. Nutrition & Metabolism, 16, Article No. 22. [Google Scholar] [CrossRef] [PubMed]
[28] Xu, Y., Xu, C., Huang, J., Xu, C. and Xiong, Y. (2024) Astragalus Polysaccharide Attenuates Diabetic Nephropathy by Reducing Apoptosis and Enhancing Autophagy through Activation of Sirt1/FoxO1 Pathway. International Urology and Nephrology, 56, 3067-3078. [Google Scholar] [CrossRef] [PubMed]
[29] Almalki, W.H. and Salman Almujri, S. (2024) Oxidative Stress and Senescence in Aging Kidneys: The Protective Role of SIRT1. EXCLI Journal, 23, 1030-1067.
[30] Qian, X., Zhao, J., Yeung, P.Y., Zhang, Q.C. and Kwok, C.K. (2019) Revealing lncRNA Structures and Interactions by Sequencing-Based Approaches. Trends in Biochemical Sciences, 44, 33-52. [Google Scholar] [CrossRef] [PubMed]
[31] Saghafi, T., Taheri, R.A., Parkkila, S. and Zolfaghari Emameh, R. (2019) Phytochemicals as Modulators of Long Non-Coding RNAs and Inhibitors of Cancer-Related Carbonic Anhydrases. International Journal of Molecular Sciences, 20, Article No. 2939. [Google Scholar] [CrossRef] [PubMed]
[32] Guo, J., Liu, Z. and Gong, R. (2019) Long Noncoding RNA: An Emerging Player in Diabetes and Diabetic Kidney Disease. Clinical Science, 133, 1321-1339. [Google Scholar] [CrossRef] [PubMed]
[33] Chen, Z., Liang, H., Yan, X., Liang, Q., Bai, Z., Xie, T., et al. (2023) Astragalus Polysaccharide Promotes Autophagy and Alleviates Diabetic Nephropathy by Targeting the lncRNA Gm41268/PRLR Pathway. Renal Failure, 45, Article ID: 2284211. [Google Scholar] [CrossRef] [PubMed]
[34] 王兴红, 张福华, 孙静, 等. 基于TXNIP/NLRP3信号通路研究根皮素对糖尿病肾病小鼠肾脏自噬和纤维化的影响[J]. 中药药理与临床, 2023, 39(9): 31-38.
[35] Liu, J., Xiao, Q., Xiao, J., Niu, C., Li, Y., Zhang, X., et al. (2022) Wnt/β-Catenin Signalling: Function, Biological Mechanisms, and Therapeutic Opportunities. Signal Transduction and Targeted Therapy, 7, Article No. 3. [Google Scholar] [CrossRef] [PubMed]
[36] 鲍芳, 宋杰, 代喆, 等. 黄芪多糖通过失活Wnt信号通路抑制高糖诱导下肾小管上皮细胞凋亡[J]. 中药材, 2019, 42(2): 414-417.

为你推荐